ORION CORPORATION STOCK EXCHANGE RELEASE 13 JUNE 2014 at 9.30
200,000 Orion A-shares converted into B-shares
In accordance with Section 3 of the Articles of Association of Orion
Corporation, 200,000 A-shares have been converted into 200,000 B-shares. The
conversion has been entered into the Trade Register on 13 June 2014.
The total number of shares in Orion Corporation is 141,257,828 which, after the
conversion, consists of 41,522,816 A-shares and 99,735,012 B-shares.
Olli Huotari Jari Karlson
SVP, Corporate Functions CFO
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had
about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.